Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Colorectal Neoplasms
  • Dermatologic Agents
  • Drug Eruptions
  • Premedication
  • Receptor, Epidermal Growth Factor

abstract

  • The pre-emptive skin treatment regimen was well tolerated. The incidence of specific >or= grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group. Patients in the pre-emptive group reported less QOL impairment than patients in the reactive group.

publication date

  • March 10, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.21.7828

PubMed ID

  • 20142600

Additional Document Info

start page

  • 1351

end page

  • 7

volume

  • 28

number

  • 8